Jennifer Jones,
NIH Stadtman Investigator, Head of Transnational Nanobiology, Laboratory of Pathology,
Center for Cancer Research, National Cancer Institute
Dr. Jones is NIH Stadtman Investigator, Head of Transnational Nanobiology, Laboratory of Pathology at the Center for Cancer Research, National Cancer Institute, who is developing, refining, and applying advanced high-resolution flow cytometric methods to the characterization of EV subsets. She initiated/cofounded the international ISEV-ISAC-ISTH EV Flow Cytometry Working Group, to support the development of consensus best practices and standardization methods for the field. The ultimate goal of her research is to develop a new class of EV-based biomarkers (and methods for anlyzing those EVs) that will enable adaptve therapeutic strategies, where individual patient treatments are customized based on early responses to treatment.
Mt-SEA Pipeline: High Throughput Flow Cytometric Analysis of Exosomes in Clinical Biofluids
Wednesday, 28 March 2018 at 18:00
Add to Calendar ▼2018-03-28 18:00:002018-03-28 19:00:00Europe/LondonMt-SEA Pipeline: High Throughput Flow Cytometric Analysis of Exosomes in Clinical BiofluidsSELECTBIOenquiries@selectbiosciences.com
Because Extracellular Vesicles (EVs) carry surface receptors that are
characteristic of their cells of origin, EVs have tremendous potential
as non-invasive biomarkers for diagnosis, risk-stratification, treatment
selection, and treatment monitoring. We developed a first-in-class
pipeline to characterize EV heterogeneity and provide high-sensitivity
quantification of informative EVs in biofluids before, during, and after
treatment. By combining multiplex assays with high-resolution, single
EV flow cytometric methods together into a Mutiplex-to-Single EV
Analysis (Mt-SEA) pipeline, we are able to characterize a broad range of
relevant EV subsets, while also accurately measuring the concentration
of specific EV populations. Detection of tumor-associated EVs and
detection of EV repertoire changes during treatment paves the way to
future evaluation of EVs as as biomarkers for use in personalized,
adaptive therapies.
Add to Calendar ▼2018-03-28 00:00:002018-03-29 00:00:00Europe/LondonCirculating Nucleic Acids and Circulating Rare Cells: Liquid Biopsy for Early Cancer Detection SELECTBIOenquiries@selectbiosciences.com